Consumer-Use Baby Monitors Have Little Proven Benefit for Healthy Infants

"These devices are marketed aggressively to parents of healthy babies, promising peace of mind about their child's cardiorespiratory health," said pediatrician and safety expert Christopher P. Bonafide, MD, MSCE, of Children's Hospital of Philadelphia (CHOP). "But there is no evidence that these consumer infant physiological monitors are life-saving or even accurate, and these products may cause unnecessary fear, uncertainty and self-doubt in parents."

Bonafide and colleagues wrote an article in today's issue of the Journal of the American Medical Association (JAMA). His co-authors are Elizabeth E. Foglia, MD, MSCE, a neonatologist at CHOP, and David T. Jamison, executive director of Health Devices at ECRI Institute, a nonprofit research organization that evaluates medical devices, procedures and processes.

The researchers focused on five models of infant physiological monitors introduced over the past two years, with names such as MonBaby, Baby Vida and Owlet, at costs ranging from $150 to $300. The manufacturers do not directly claim their products treat, diagnose or prevent disease, and the monitors have not been regulated as medical devices by the U.S. Food and Drug Administration (FDA). However, an advertising video for Owlet mentions sudden infant death syndrome (SIDS) and suggests that the device may notify parents that something is wrong.

ECRI Institute has concerns regarding safety and effectiveness of these products. "There is no publicly available evidence that these baby monitors are accurate in measuring a baby's vital signs," said Jamison. "And since these baby monitors are not regulated by the FDA, we have to question what testing has been done to assure the safety and quality of these designs."

Even if these consumer monitors prove to be accurate, said Bonafide, "there is a serious question whether these are appropriate in monitoring healthy infants. A single abnormal reading may cause overdiagnosis—an accurate detection that does not benefit a patient." For example, he says, one reading of low oxygen saturation that would resolve on its own may trigger a visit to an emergency department, followed by unnecessary blood tests, X-rays and even hospital admission.

As a neonatologist, Foglia cares for sick infants daily in the intensive care unit and says parents often ask if they should use an apnea monitor when their babies first come home. She added, "In the future, some physiological monitors may offer real benefits to vulnerable infants at home, but we have no evidence now that these devices are safe, accurate or effective."

Christopher P. Bonafide et al, "The Emerging Market of Smartphone-Integrated Infant Physiological Monitors," Journal of the American Medical Association, Jan. 24-31, 2017.
http://doi.org/10.1001/jama.2016.19137

For more information about ECRI Institute, see http://www.ecri.org

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide.  Its pediatric research program is among the largest in the country.  In addition, its unique family-centered care and public service programs have brought the 535-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Natalie Virgilio
Children's Hospital of Philadelphia
(267) 426-6246
[email protected]

SOURCE The Children's Hospital of Philadelphia

Related Links

http://www.chop.edu